Related references
Note: Only part of the references are listed.Granulocyte-Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression A Double-Blind, Randomized, Placebo-controlled Multicenter Trial
Christian Meisel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors
Martin Ploder et al.
CLINICAL SCIENCE (2009)
New promises for manipulation of kynurenine pathway in cancer and neurological diseases
Gabriele Costantino
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases
P. H. Tan et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Indoleamine 2,3-Dioxygenase in Intestinal Immunity and Inflammation
Bobby J. Cherayil
INFLAMMATORY BOWEL DISEASES (2009)
Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial
Robert Carr et al.
LANCET (2009)
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms
Joerg C. Schefold et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host
Teresa Zelante et al.
MICROBES AND INFECTION (2009)
INCREASED PLASMA KYNURENINE VALUES AND KYNURENINE-TRYPTOPHAN RATIOS AFTER MAJOR TRAUMA ARE EARLY INDICATORS FOR THE DEVELOPMENT OF SEPSIS
Tim T. Loegters et al.
SHOCK (2009)
Exploring the mechanism of tryptophan 2,3-dioxygenase
Sarah J. Thackray et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2008)
Pyocalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations
Kenneth L. Becker et al.
CRITICAL CARE MEDICINE (2008)
Monitoring immune dysfunctions in the septic patient: A new skin for the old ceremony
Guillaume Monneret et al.
MOLECULAR MEDICINE (2008)
Sepsis: Time has come to focus on the later stages
Joerg Christian Schefold et al.
MEDICAL HYPOTHESES (2008)
Colony-stimulating factors in inflammation and autoimmunity
John A. Hamilton
NATURE REVIEWS IMMUNOLOGY (2008)
The influence of corticosteroids on the release of novel biomarkers in human endotoxemia
Martijn D. de Kruif et al.
INTENSIVE CARE MEDICINE (2008)
IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells
Marcelo Hill et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
A novel selective extracorporeal intervention in sepsis: Immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5A
Joerg C. Schefold et al.
SHOCK (2007)
IDO and regulatory T cells:: a role for reverse signalling and non-canonical NF-κB activation
Paolo Puccetti et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Immunosuppression via tryptophan catabolism: The role of kynurenine pathway enzymes
Maria Laura Belladonna et al.
TRANSPLANTATION (2007)
Markers for sepsis diagnosis: What is useful?
Konrad Reinhart et al.
CRITICAL CARE CLINICS (2006)
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression:: A multicenter standardized study
WD Döcke et al.
CLINICAL CHEMISTRY (2005)
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
M Platten et al.
SCIENCE (2005)
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration
M Heikenwalder et al.
NATURE MEDICINE (2004)
Tryptophan and the immune response
JR Moffett et al.
IMMUNOLOGY AND CELL BIOLOGY (2003)
Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis
A Nierhaus et al.
INTENSIVE CARE MEDICINE (2003)